Chest
-
The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a "gray zone" of unclear clinical significance. ⋯ In this study, diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value was the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.
-
Randomized Controlled Trial Retraction Of Publication
TEMPORARY REMOVAL: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BRENSOCATIB IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS - THE ASPEN TRIAL.
This abstract has been temporarily removed at the request of the author. A replacement will appear as soon as possible, or the abstract will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.
-
Meta Analysis
Pulmonary hypertension in interstitial lung disease: a systematic review and meta-analysis.
Pulmonary hypertension (PH) is a key complication in interstitial lung disease (ILD), with recent therapeutic advances. ⋯ PH is a common complication in ILD with significant health impacts. A standardized definition with prospective evaluation of risk-stratified assessments for PH using identified associated risk factors is warranted. Our findings provide an evidence base for validation as surrogate end points in future PH interventional trials in ILD.